Detalles de la búsqueda
1.
Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer.
Breast Cancer Res Treat
; 197(2): 307-317, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36396775
2.
Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response.
Breast Cancer Res
; 16(2): 303, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25032256
3.
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Breast Cancer Res
; 16(1): R9, 2014 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24451154
4.
Feasibility and Tolerability of Adjuvant Capecitabine-Based Chemoradiation in Patients With Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy: A Prospective Clinical Trial.
Int J Radiat Oncol Biol Phys
; 118(5): 1262-1270, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37433376
5.
Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.
Breast Cancer Res
; 13(6): 224, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22114931
6.
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Front Oncol
; 11: 810023, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35223458
7.
Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant Breast Cancer: Feasibility, Safety, and Toxicity.
Clin Breast Cancer
; 20(4): 344-352.e1, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234364
8.
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Clin Cancer Res
; 26(4): 821-827, 2020 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31662331
9.
Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer.
Clin Cancer Res
; 26(21): 5668-5681, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32826327
10.
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.
Cancer Res
; 77(12): 3280-3292, 2017 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28396358
11.
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
J Natl Cancer Inst
; 109(11)2017 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29059433
12.
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Cancer Res
; 76(16): 4752-64, 2016 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27197158
13.
Correction: Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer.
Cancer Res
; 79(4): 873, 2019 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30770368
14.
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
Cancer Res
; 73(13): 3817-20, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23794708
15.
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Clin Cancer Res
; 19(19): 5390-401, 2013 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23948973
16.
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Cancer Res
; 73(13): 4075-85, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23633485
17.
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
Crit Rev Oncog
; 17(1): 1-16, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22471661
18.
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.
Cancer Res
; 71(18): 5965-75, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21775521
19.
Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
Clin Cancer Res
; 15(14): 4518-20, 2009 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19584146
20.
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.
Cell Cycle
; 8(1): 18-22, 2009 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19106609